Professionals 227 Users Online

Perfusion Bioreactors Market

Increasing Growth in Biopharmaceutical Production and Increasing Investments in R&D will drive the global market for Perfusion Bioreactors over the forecast duration

Perfusion Bioreactors Market Segmented by Small Scale, Large Scale Perfusion Bioreactors for R&D, GMP

Perfusion Bioreactors Market Outlook (2023-2033)

Worldwide revenue from the perfusion bioreactors market stands at US$ 345.6 Mn in 2022, with the global market estimated to expand at a CAGR of 7.2% to reach US$ 747.6 Mn by the end of 2033.

Perfusion Bioreactors Market Size (2022)

US$ 345.6 Mn

Projected Market Value (2033)

US$ 747.6 Mn

Global Market Growth Rate (2023-2033)

7.2% CAGR

Market Share of Top 5 Countries

51.9%

As assessed by Persistence Market Research, small scale bioreactors (< or = 1,000 litres) is set to contribute the largest share of 63.9% among the scale category in 2023. The perfusion bioreactors market holds 10.8% of the global bioreactors market valued at US$ 3.2 Bn in 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of Perfusion Bioreactors Market from 2016 to 2022 Vs Market Outlook for 2023 to 2033

The use of perfusion bioreactors has historically increased from 2016 to 2022 at a CAGR of about 6.6%.

Bioreactor use is expanding as a result of rising consumer demand for products with more efficiency, lower costs, and higher production. The next revolution in bioprocessing will be brought about by perfusion bioreactor technologies. Perfusion bioreactors can outperform fed-batch bioprocessing in terms of manufacturing speed, productivity, and capital requirements due to existing technology.

Commercial-scale and clinical bioreactor technology has advanced recently, particularly in systems based on single-use bioreactors. These developments led to a rise in the use of perfusion bioreactors in the production of goods for sale.

Regulatory agencies have introduced process analytical technologies and quality-by-design principles as a result of the rising demand for biotherapeutics. These ideas seek to increase the quality of biopharmaceuticals by measuring, analysing, and monitoring bioprocess factors. Bioreactor technology has made remarkable strides, and the market is anticipated to grow in the forecasted period.

  • In September 2020, Thermo Fisher Scientific opened a new bioprocessing collaboration centre in St. Louis. This accelerated innovation in biologics manufacturing by combining bioproduction and pharmaceutical services.
  • In February 2021, Thermo Fisher Scientific officially completed the acquisition of Mesa Biotech.

The market is becoming more consolidated as a result of the key companies' pursuit of mergers, acquisitions, and expansion. Additionally, top manufacturers are putting a lot of effort into upgrading their manufacturing facilities.

  • For instance, Sartorius completed the acquisition of select Danaher Corporation life science companies effective 2020.

For complex biologicals in cell culture, like fusion proteins and antibodies, bioprocessing is frequently used. The biopharmaceutical business is now focusing on improving manufacturing efficiency to boost output and meet consumer demand.

For the generation of cell lines that have no negative effects or toxicity toward host cells or unstable products, perfusion technology is widely used and well-suited.

Bioreactors using the perfusion technique enable increased product scalability with sizes up to 1,000 L operating volume. The loss and death of cells are being reduced via perfusion technology. Compared to a fed-batch method, these technologies give high-density viable cells.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

How are Manufacturers Expanding the Market?

“Increasing Growth in Biopharmaceutical Production and Increasing Investments in R&D”

The global biopharmaceutical industry's rising need for high-quality bioprocesses is expected to drive the market for perfusion bioreactors.

Because companies enhance manufacturing capacity and lower manufacturing costs, technology transfers have a significant influence on biopharmaceutical businesses in poor economies.

Manufacturers are concentrating on advancements to remain ahead of the competition as it grows. As a result, they use novel ideas to obtain perfusion bioreactors that are affordable. Perfusion bioreactors are anticipated to see expansion in the near future as a result of new innovative product development that is non-toxic to cell culture during bioprocessing.

In order to extend their technology development skills to meet the needs of bioreactors, major players are boosting their R&D expenditures. It has been noted that regulatory bodies have boosted the number of perfusion bioreactor approvals in recent years.

A number of actions have been done by regulatory agencies to increase the percentage of first actions that are approved. Therefore, significant players are focusing on investment in R&D, thus boosting market expansion.

Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

What are the Factors Restraining Demand for Perfusion Bioreactors?

High Cost of Equipment Hampering Market Growth

Due to rising demand and the cost of raw materials, instrumentation prices have been steadily rising. Perfusion bioreactors are highly expensive. This will restrict their market penetration in emerging and low-income nations, which will somewhat restrain market expansion overall.

Leading producers of perfusion bioreactors have the strategy of launching cutting-edge goods in response to patient demands. Due to this feature, market participants are engaged in competitive rivalry.

  • For instance, Getinge released a new, comprehensive system solution for the setup of multi-use bioreactors from Applikon in March 2021.

Installation of advanced equipment at an organisation necessitates the use of trained personnel. Because of this, having a technical background is even more important, and it can be challenging for employees to match their skill sets to the company’s needs. The perfusion bioreactors market may be affected as a result of the biopharmaceutical industry's inability to expand due to a shortage of experienced workers and instrument operating knowledge.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

How come the U.S. Market Boom for Perfusion Bioreactors?

“Developed Healthcare Infrastructure in the U.S.”

The U.S. is set to account for a 29.4% share of the global market in 2023, and a similar trend is expected over the forecast period. Due to increased development and research of novel biologics and recent approvals of biological products, the total industry is anticipated to rise steadily.

CMO/CDMO service use is expanding, which is fuelling market expansion. Government funding for new and continuing clinical research is also fuelling the demand for perfusion bioreactors in the United States.

The U.S. market is increasing due to the increasing demand for high-quality bio-production, a growing adaption of perfusion bioreactors, increasing biopharmaceutical production, and increasing investments in R&D.

For instance,

  • The Boston biotech hub's Sartorius launched a new Customer Interaction Centre in North America in 2020 to expand its operations and capabilities.

Why is China Emerging as a Prominent Market for Perfusion Bioreactors?

“Increasing Investment in R&D”

China held the largest market share of 46.9% of the East Asia Market for perfusion bioreactors in 2022, and it is anticipated that the tendency will last the entire projected period.

The two elements driving market expansion in China are the country's large population and the immense potential for the growth of emerging economies. The majority of pharmaceutical industry participants are paying close attention to developing nations like China.

However, some of the obstacles for international manufacturers to enter the market include local rivalry and a lack of established regulatory policies. Additionally, the government support for regional manufacturing hubs is one of the main reasons why china is growing.

  • In 2021, Sartorius expands its presence in China by establishing a new customer interaction centre in Beijing.

In the upcoming years, investment in R&D is anticipated to rise across the country, particularly in nations such as China will boost the market.

Will India be a Lucrative Market for Perfusion Bioreactors?

“Increasing Healthcare Spending”

India dominates the South Asia market with a current market share of 28.5% in 2022 and is projected to expand at a CAGR of 5.6% during the forecast period.

Increasing wealth, easier access to healthcare services, changing lifestyle, and an increase in demand for high-quality healthcare, are all factors, which are contributing to market expansion in India.

Perfusion bioreactors may produce a sizable amount of product with minimal process scaling up. This can speed up the process of producing enough doses for clinical testing. Faster process development may result from easier consistency of quality achievement, which will boost this market in India.

India’s market is growing due to its high population and increasing awareness among people related to their health, Indian government focusing on the healthcare sector and increasing funding which will influence positively on the growth of the perfusion bioreactors market.

Category-wise Insights

Why is Demand for Small Scale Bioreactors (< or = 1,000 litres) Continuously Rising?

“Increasing Technological Development.”

Due to technological developments, small-size bioreactors (1,000 litres or less) dominated the global market and is set to contribute the largest share of 63.9% among the scale category in 2023.

Bioreactors using the perfusion technique enable increased product scalability with sizes up to 1,000 L operating volume. Compared to the fed-batch method, these technologies give high-density viable cells.

For instance, the perfusion technique offers a cell density of about 5 × 107 cells per millilitre as opposed to fed-batch, which offers a cell density of 2 × 107 cells per millilitre. The expansion of this area is a result of technological developments in the biopharma industry as a whole.

Which Type of Application Takes the Highest Share in Perfusion Bioreactors?

In 2023, compared to perfusion bioreactors for GMP, perfusion bioreactors for R&D will dominate with 56.7% of the global market share in the application segment.

Increasing Investments in R&D is the main reason behind its domination in the application segment. Nowadays, every country is focusing on their R&D sectors and that is why the government from the particular country provides funding to companies to spend it on novel innovations.

R&D refers to the actions businesses do to innovate, offer fresh goods and services, or enhance their current selection. By addressing emerging consumer demands or market needs, R&D enables a business to stay one-step ahead of its rivals; hence, perfusion bioreactors for R&D dominate in the application segment.

Why are Biopharmaceutical Companies Key to Market Growth for Perfusion Bioreactors?

In 2023, biopharmaceutical businesses will hold a market share of 44.1% globally, which is the highest among academic and research institutes, contract research organizations (CRO) and contract manufacturing organizations (CMO).

Perfusion bioreactors are primarily used for tissue engineering, cell culture, and producing media for in vitro cell growth. Biopharmaceutical firms carry out this procedure involving cells and tissues, which explains why they dominate the end-user category.

Competitive Landscape

The perfusion bioreactors market is highly consolidated due to the existence of major players who operate in this industry. Market participants are also working to increase their regional and worldwide reach through product launches, acquisitions, and distribution channel expansions.

For instance,

  • To fulfil the rising need for biotechnology solutions, Cytiva and Pall Corporation announced a 1.5 billion USD investment over two years in July 2021.
  • A leading business in the quickly expanding field of advanced bioreactor systems for biopharmaceutical production and research, Applikon Biotechnology B.V., made an announcement in December 2019 that Getinge had reached an agreement to purchase 100% of the company's shares from Applikon Biotechnology Holding.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the perfusion bioreactors market, which are available in the full report.

Perfusion Bioreactors Market Report Scope

Attribute

Details

Forecast Period

2023-2033

Historical Data Available for

2016-2022

Market Analysis

  • USD Million for Value
  • Units for Volume

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • BENELUX
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC Countries
  • South Africa
  • North Africa

Key Market Segments Covered

  • Scale
  • Application
  • End User
  • Region

Key Companies Profiled

  • Sartorius AG
  • Cell Culture Company
  • Cytiva (Danaher Corporation)
  • CELLEC BIOTEK AG
  • Synthecon Inc
  • Getinge (Applikon Biotechnology B.V)
  • Zellwerk GmbH
  • Thermo Fisher Scientific Inc
  • Eppendorf AG
  • Infors HT
  • 3D Biotek LLC

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Customization & Pricing

Available upon Request

Key Segments of the Perfusion Bioreactors Industry Research

By Scale:

  • Small Scale Perfusion Bioreactors (< or = 1,000 Litres)
  • Large Scale Perfusion Bioreactors (> 1,000 Litres)

By Application:

  • Perfusion Bioreactors for R&D
  • Perfusion Bioreactors for GMP

By End User:

  • Biopharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organization (CRO)
  • Contract Manufacturing Organization (CMO)

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Sartorius AG
  • Cell Culture Company
  • Cytiva (Danaher Corporation)
  • CELLEC BIOTEK AG
  • Synthecon Inc
  • Getinge (Applikon Biotechnology B.V)
  • Zellwerk GmbH
  • Thermo Fisher Scientific Inc
  • Eppendorf AG
  • Infors HT
  • 3D Biotek LLC.

- Frequently Asked Questions -

The global market for perfusion bioreactors is valued at around US$ 345.6 Mn in 2022.

By 2033, sales of perfusion bioreactors are anticipated to expand at a pace of 7.2% and reach US$ 747.6 Mn.

Demand for perfusion bioreactors increased at 6.6% CAGR from 2016 to 2022.

With a combined market share of 51.9% in 2022, the U.S., China, Germany, U.K. and France accounted for the majority of demand for perfusion bioreactors.

The U.S. is set to account for a 29.4% share of the global market in 2023.

Sartorius AG, Cell Culture Company and Cytiva (Danaher Corporation) are the top three manufacturers of the perfusion bioreactors market.

China held a share of 46.9% in the East Asian market in 2022.

The market for perfusion bioreactors in Germany enjoy a value share of around 18.0% within the European market in 2022.

India dominates the South Asia market with a current market share of 28.5% in 2022 and is projected to expand at a CAGR of 5.6% during the forecast period.

The U.K. market is expected to grow at a CAGR of 5.5% during the forecast period.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate